Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

(2016) P. D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab

(2016) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary

(2015) Péter Lakatos et al.   CALCIFIED TISSUE INTERNATIONAL

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

(2015) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Fracture predictive ability of physical performance tests and history of falls in elderly women: a 10-year prospective study

(2015) A. Wihlborg et al.   OSTEOPOROSIS INTERNATIONAL

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

(2015) L. Karlsson et al.   OSTEOPOROSIS INTERNATIONAL

Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States

(2015) Lung-I Cheng et al.   Journal of Managed Care & Specialty Pharmacy

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

(2014) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™

(2014) S. W. Wade et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany

(2013) Peyman Hadji et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Persistence with osteoporosis medication among newly-treated osteoporotic patients

(2013) Job F. M. van Boven et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

(2013) Chris Recknor et al.   OBSTETRICS AND GYNECOLOGY

The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis

(2013) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Osteoporosis in the European Union: a compendium of country-specific reports

(2013) A. Svedbom et al.   Archives of Osteoporosis

Osteoporosis in the European Union: medical management, epidemiology and economic burden

(2013) E. Hernlund et al.   Archives of Osteoporosis

Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan

(2012) Sally W. Wade et al.   BONE

Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

(2012) Kurt A. Kennel et al.   MAYO CLINIC PROCEEDINGS

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials

(2011) Young Ho Lee et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Uptake of treatment for osteoporosis and compliance after bone density measurement in the community

(2009) M. N. Dugard et al.   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

(2009) F.-E. Cotté et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Predictive Validity of a Medication Adherence Measure in an Outpatient Setting

(2008) Donald E. Morisky et al.   Journal of Clinical Hypertension

Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions

(2008) Becky A Briesacher et al.   PHARMACOTHERAPY

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH